OBJECTIVE: To probe into the efficacy of salmeterol xinafoate and fluticasone propionate inhalation aerosol combined with montelukast sodium chewable tablets in the clinical treatment of asthma. METHODS: Totally 150 patients with asthma admitted into Qinghai Red Cross Hospital from Sept. 2017 to Jan. 2019 were extracted

the clinical data were retrospectively analyzed. According to the treatment method

all patients were divided into the observation group（ n = 77） and the control group（ n = 73）. The control group was treated with montelukast sodium chewable tablets

while the observation group additionally received salmeterol xinafoate and fluticasone propionate inhalation aerosol based on the control group. Differences of clinical efficacy

improvement of symptoms

pulmonary function indicators [forced vital capacity（ FVC）

forced expiratory volume at 1 second（ FEV1）

FEV1/FVC and peak expiratory flow（ PEF） ]

and immune function indicators [interleukin 4（ IL-4）

interferon gamma（ INF-γ）

and immunoglobulin E（ Ig E） ] of two groups were compared. RESULTS: After treatment

the total effective rate in the observation group was significantly higher than that in the control group [96. 10%（ 74/77） vs. 84. 93%（ 62/73） ]

the difference was statistically significant（ P<0. 05）. After treatment

the remission time and disappearance time of cough in the observation group were significantly shorter than those in the control group

with statistically significant differences（ P<0. 05）. After treatment

the levels of FVC

FEV1

FEV1/FVC

PEF

and INF-γ in two groups were significantly higher than those before treatment

and the observation group was significantly higher than the control group

the differences were statistically significant（ P<0. 05）. After treatment

the levels of IL-4 and Ig E in two groups were significantly lower than those before treatment

and the observation group was significantly lower than the control group

the differences were statistically significant（ P<0. 05）. CONCLUSIONS: The efficacy of salmeterol xinafoate and fluticasone propionate inhalation aerosol combined with montelukast sodium chewable tablets in the clinical treatment of asthma is significant

which can regulate the immune function

improve patients’ lung function and clinical symptoms.